The Role of CAR NK Cells: Competition or Compliment to CAR T-Cell Therapy?
June 13th 2021New studies into chimeric antigen receptor (CAR)–engineered natural killer (NK) cells has shown promising results, explained Ulrike Köhl, PhD, MD, professor of immune oncology and director of the Institute for Clinical Immunology at the University of Leipzig in Germany.
Brexucabtagene Autoleucel Safe, Efficacious as Therapy for Pediatric B-Cell ALL in ZUMA-4
June 13th 2021Long-term efficacy assessment of brexucabtagene autoleucel demonstrated high rates of MRD negativity and CR rates in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Speakers Suggest Moving Newer Agents Into Earlier Lines in MM
June 13th 2021Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.
Cilta-Cel Significantly Improved Response and Survival Over Conventional Therapy for R/R MM
June 12th 2021Treatment with the CAR T-cell therapy ciltacabtagene autoleucel significantly improved outcomes for patients with relapsed or refractory multiple myeloma when compared with conventional therapies.
CART-ddBCMA Elicits 100% ORR in Relapsed/Refractory Multiple Myeloma
June 6th 2021The autologous CAR T-cell product CART-ddBCMA was found to elicit a 100% objective response rate in patients with relapsed/refractory multiple myeloma, with deep and durable responses noted in those with poor prognostic factors.
Larry Anderson, MD, PhD, Discussed Updated Results of the KarMMa Trial at ASCO
June 6th 2021CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 2021 ASCO Annual Meeting to talk about updated data from the KarMMa trial of CAR T-cell therapy idecabtagene vicleucel to treat patients with relapsed or refractory multiple myeloma.
FDA Grants RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma
April 21st 2021The FDA granted a Regenerative Medicine Advanced Therapy designation to the allogeneic chimeric antigen receptor T-cell therapy as a potential treatment for patients with relapsed/refractory multiple myeloma.